Overcoming intellectual property phobia in China
China is a big market with a lot of potential but many pharma industry firms still avoid doing business in the country because of fears that their intellectual property (IP) cannot be protected.
China is a big market with a lot of potential but many pharma industry firms still avoid doing business in the country because of fears that their intellectual property (IP) cannot be protected.
Fewer first cycle new drug approvals by the US Food and Drug Administration (FDA) could be the first evidence of a toughening regulatory environment, according to new research.
Minimising the risk of cross-contamination in the production of medicines for use in clinical trials is a major challenge for manufacturers, who need to implement safety measures in order to avoid production failure.
A "faster and cheaper" blister pack machine was launched by Indian-firm Cap Tab for the first time in Europe at this year's CPhI in Paris.